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Micro-satellite instability (MSI) is relevant in the management of colorectal cancers (CRC) and relies on analysis of gene mutations, or
production of the proteins involved in DNA mismatch repair (e.g. MLH1, MSH2). p53 mutation is also relevant in MSI, but high-level
CRC (MSI-H) demonstrate fewer mutations than low-level (MSI-L) or stable (MSS) cancers. Recently, the importance of gene activity
(transcription) in MSI has been identified, where rather than being mutated genes have been downregulated. In this study, 67 sporadic
CRC and eight samples of normal bowel were analysed for MSI status (by SSCP) and levels of MLH1, MSH2 and p53 gene
transcription (by RT–PCR and scanning densitometry). Micro-satellite instability correlated with gender and site, with more MSI-H
CRC in females (Po0.02) and in the right colon (Po0.04). In MSI-H, p53 transcription was markedly reduced (Po0.003). Compared
to normal bowel, MLH1 transcription was elevated in all cancers (Po0.01), while MSH2 transcription was elevated only in MSI-H
(Po0.04). There was a direct correlation between MLH1 and MSH2 transcription (Po0.001). Although fewer mutations are
reported in MSI-H than MSI-L/MSS, these results suggest that reduced p53 transcription might account for decreased tumour
suppression in MSI-H. The direct correlation between MLH1 and MSH2 transcription suggests that control of these genes might be
coordinated.
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Colorectal cancers (CRC) exhibit two distinct forms of genomic
instability believed to underlie their development. Chromosomal
instability (CIN) is associated with loss of function of the tumour-
suppressor gene p53 (Lengauer et al, 1997) and hence the G1-to-S
phase checkpoint of the cell cycle, resulting in ‘accumulation’ of
mutations, leading to tumorigenesis. In contrast, micro-satellite
instability (MSI) results from loss of function of the mismatch
repair (MMR) genes, principally MLH1 and MSH2 (Papadopouos
and Lindblom, 1997). With normal functioning MMR genes, errors
in DNA replication are identified, the ‘mutated’ sequences excised
and the correct sequence re-synthesised. However, loss of MMR
leads to an accumulation of errors within micro-satellite regions,
resulting in the disturbance of regulation and/or activity of a
number of genes such as TGFbRII (Parsons et al, 1995) or TCF-4
(Duval et al, 1999), again leading to tumorigenesis.
Micro-satellite instability occurs in almost all hereditary
nonpolyposis CRC (HNPCC; Aaltonen et al, 1993), which accounts
for o1% of CRC overall (Percesepe et al, 2001; Samowitz et al,
2001) and approximately 15% of sporadic CRC (Kim et al, 1994;
Feeley et al, 1999; Gryfe et al, 2000; Wright et al, 2000). In the
National Cancer Institute (NCI) guidelines for the detection of MSI
(Boland et al, 1998), a panel of micro-satellite loci containing two
mono-nucleotide repeats (BAT25 and BAT26) and three di-
nucleotide repeats (D2S123, D5S346 and D17S250) are investi-
gated. Cancers are then subdivided into three groups; high-level
MSI (MSI-H) that demonstrate instability in 430–40% of loci,
low-level MSI (MSI-L) instability of o30–40% of loci, and stable
cancers (MSS) with no instability, that is, all loci normal.
When more (than the five recommended) micro-satellite
regions are examined, almost all CRCs demonstrate some degree
of MSI (usually MSI-L; Laiho et al, 2002). As a result, there is
controversy as to whether MSS and MSI-L cancers are distinctly
separate or are similar. Jass et al (2002), among others, favour a
clear and distinct separation between these groups, as the
identification of ‘milder mutator’ phenotype MSI-L cancers can
be of clinical significance. MSI-H cancers have distinctive clinical
features such as large tumour size, proximal predominance, poor
histological differentiation, mucinous growth and lymphocytic
infiltration, with better prognosis compared to stage-matched MSS
cancers (Lothe et al, 1993; Kim et al, 1994; Boland et al, 1998; Gryfe
et al, 2000).
Although mutations in MMR genes are believed to account for
most HNPCC, the mechanism responsible for the MSI-H
phenotype in sporadic CRC seems to involve methylation of
MMR gene sequences, resulting in downregulation of gene
expression (transcription) and subsequently less functional
protein (Kane et al, 1997; Cunningham et al, 1998; Herman et al,
1998; Kuismanen et al, 1999). Since overexpression of MLH1 and
MSH2 induces apoptosis (Zhang et al, 1999), the relationships
between these genes and the mutation and function of the tumour-
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ssuppressor gene p53 have been of interest. There appears to be an
inverse relationship between MSI ‘severity’ (status) and p53
mutation (Cottu et al, 1996; Breivik et al, 1997; Olschwang et al,
1997; Forster et al, 1998; Iacopetta et al, 1998), which seems
paradoxical as a greater rate of p53 mutation in higher ‘mutator
phenotype’ MSI-H cancers might be expected. The mechanism
underlying this effect is unclear but might relate to the degree of
DNA methylation and consequently gene activity in the MMR
genes (Cunningham et al, 1998; Kuismanen et al, 1999), although
this has not been described.
Numerous studies have investigated the relationship between
MLH1, MSH2 and p53 in MSI, by examining principally mutations
in the gene DNA sequences, or production of the relevant protein.
Few if any studies, however, have examined gene activity, that is,
gene transcription, which has particular relevance in under-
standing the control of gene regulation in the process(es) of
tumour development and progression. Therefore in this study, the
activity (transcription) of MLH1, MSH2 and p53 in sporadic CRC
with MSI is investigated by reverse transcription–polymerase
chain reaction (RT–PCR) analysis of total cellular RNA extracted
from archival wax-embedded samples.
MATERIALS AND METHODS
Sample collection
The study was performed after approval by the Joint University
College London/University College Hospitals London Committees
on the Ethics of Human Research. There were 67 paraffin-
embedded cancer archival samples from 67 patients who had
undergone colonic resection and had been followed up for at least
7 years with no evidence of metachronus cancers. Normal control
samples of colon were obtained from eight patients undergoing
colonic resection, seven for cancer and one for a large tubullo-
villous adenoma, and were paraffin-embedded. Gender, age, cancer
site and Dukes’ classification were recorded. Cancers were defined
as right-sided when proximal, and left-sided when distal, to the
splenic flexure.
Analysis of MSI
Micro-satellite instability status was determined by PCR-SSCP
(single-stranded conformational polymorphism; Sengupta et al,
1997), using a panel of six micro-satellite loci, three mono-
nucleotide (BAT25, BAT26, BAT40) and three di-nucleotide repeat
regions (D5S346, D2S123 and D17S250; Boland et al, 1998).
Analysis of gene transcription
Total cellular RNA was extracted from paraffin-embedded samples
using the commercially available Ambion
s RNA isolation kit
(Ambion
s Ltd; Cambridgeshire, UK). Samples were prepared as
follows: two 20mm paraffin-embedded sections were de-paraffi-
nised in xylene (BDH
s; Merck, UK), washed with 100% ethanol
and then dried for 5min in air (at room temperature). Tissue was
digested by treatment with proteinase K (1mgml
 1) for 2h at
451C and then solubilised in 600ml guanidinium-based
RNA extraction buffer. Following extraction with 700ml acid
phenol:chloroform, RNA was precipitated in isopropanol (BDH
s;
Merck, UK) using linear acrylamide as a carrier. The precipitated
RNA was washed in 75% ethanol, re-dissolved in 10ml RNA
Storage Solutiont and then stored at  201C. Complimentary DNA
(cDNA) was produced from 4mg of total cellular RNA using
MMLV-RT (Sigma
s, UK) and random hexamers (New England
BioLabs
s Inc, USA) according to a standard protocol. Subsequent
PCR reactions were performed on 600ng of cDNA, amplified in a
50ml reaction using DNA polymerase REDTaqt (Sigma
s, UK) in
a Techne Genius Thermocycler (Jencons PLS, UK). A standard ‘hot
start’ PCR was used in conjunction with cycles of increasing
stringency, to a total of 40 cycles of amplification as follows: 941C
(45s), 501C (45s), 721C (45s) for 10 cycles, then 941C (45s), 551C
(45s), 721C (45s) for 10 cycles and then 941C (45s), 581C (45s),
721C (45s) for a further 20 cycles.
For the amplification of test genes, sets of primers were designed
specifically to have small amplicon sizes (to maximise the yield),
and which spanned at least one exon–exon boundary to avoid the
aberrant amplification of any contaminating DNA sequences
(Masuda et al, 1999). Furthermore, to ensure that for each test
gene analysed the sequences amplified were reflective of processed
and full-length messenger RNA, two sets of primers were utilised
(in separate PCR reactions), designed to amplify sequences
towards the 50 and separately, the 30 regions of each gene. The
primer sequences used are presented in Table 1. PCR products
were resolved on 2% agarose (BDH
s, Merck, UK), and transcripts
analysed by scanning densitometry (measured as total integrated
optical density, IOD) using LabWorks Imaging and Acquisition
software (UVP, Cambridge, UK). Levels of gene transcription were
determined from the ratio of test gene PCR band IOD and that of
its internal control house-keeping gene glycerylaldehyde 3-
dehydrogenase (GAP-3). Samples were included for analysis only
when there was consensus between levels of transcription in
transcripts amplified from both 50 and 30 regions. Consensus IOD
ratios were then averaged. For all samples, two separate PCR
reactions were performed with the mean IOD ratio used for further
analysis.
In order to investigate the transcription of MLH1, MSH2 and
p53 further, samples were analysed according to the presence of
mutations in particular markers, as follows: (1) no mutations (MSS
cancers), (2) mutations present only in mono-nucleotide markers
(di-nucleotide markers normal), (3) mutations present only in di-
nucleotide markers (mono-nucleotide markers normal) and (4)
mutations present in both mono- and di-nucleotide markers.
Statistics
The results were summarised using descriptive statistics and
comparisons between group ages made by Mann–Whitney U test.
The MSI status and Dukes’ staging, gender or site, or between
Dukes’ staging with gender or site, were compared by w
2 test. The
levels of gene transcription are presented as mean values with
s.e.m. (in parentheses) following analysis for uniformity and
Table 1 Primer sequences
Gene Region Primer sequence Direction Size (bp)
MLH1 50 -TGTTAAAGAGGGAGGCCTGA- Sense 92
-TGAACCTTTCACATACAATATCCA- Antisense
30 -AAGAAGGCTGAGATGCTTGC- Sense 102
-CAAAGGGGGCACATAGTTGT- Antisense
MSH2 50 -AAGGCATCCAAGGAGAATGA- Sense 106
-TGGAAGCTGACATATCATTGTTAC- Antisense
30 -GAGTCTCCACGTTCATTGGCT- Sense 103
-GAAGTTCCTCTTCCCAATTCA- Antisense
p53 50 -CCCCTCTGAGTCAGGAAACA- Sense 93
-AATCATCCATTGCTTGGGAC- Antisense
30 -AGGCCTTGGAACTCAAGGAT- Sense 106
-TTATGGCGGGAGGTAGACTG- Antisense
GAP-3 — -GAGTCAACGGATTTGGTCGT- Sense 103
-TTGAGGTCAATGAAGGGGTC- Antisense
Primer sequences used for RT–PCR analyses.
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normality. Comparisons between groups were made by one-way
analysis of variance (ANOVA) with Bonferroni’s correction to
identify differences between individual group means; all tests were
two-tailed. Correlation between factors was analysed by Pearson’s
bivariate correlation analysis. Statistical significance was accepted
at Po0.05; analyses yielding nonstatistically significant results are
not cited.
RESULTS
A total of 67 specimens (median age 73 (range 38–100) years)
from 35 males (70 (38–100) years) and 32 females (77 (53–91)
years) with CRC, and eight specimens of normal bowel (68.5 (45–
87) years) from five males (66 (57–82) years) and three females (71
(45–87) years) were obtained. The age and sex distribution was
comparable for CRC (P40.1) and normal samples (P40.1). Of the
67 CRC examined, the majority were MSS (55%; Po0.001, w
2,
Table 2), with fewer MSI-L (29%) and MSI-H (18%) cases. These
were more left-sided cancers (58%; although not significant) and
were mostly Dukes’ B (48%) or C (36%) stage (Po0.001, w
2,
Table 2).
Dukes’ stage distribution was similar in both sexes (Table 2).
While Dukes’ stage B and C cancers were of a similar distribution
in the left and right sides of the colon (Table 3), Dukes’ stage A or
D cancers were exclusively left-sided CRC (Po0.03, w
2; Table 3)
although the numbers were small.
Micro-satellite instability was related to gender with more MSI-
H (83 vs 17%), and less MSI-L (33 vs 67%) in females than males
(Po0.02, w
2; see Table 2), and to tumour site with MSI-H in right-
sided (75 vs 25%) and MSI-L in left-sided (67 vs 33%) cancers
(Po0.04, w
2; Table 3). Micro-satellite instability was unrelated to
Dukes’ stage (results not shown).
MLH1 transcription was similar in both MSS and MSI-L cancers,
but was slightly (although not significantly) elevated in MSI-H
(Figure 1). Compared to normal bowel, all cancers demonstrated
elevated levels of MLH1 transcription (all, Po0.01 vs MSS, MSI-L
and MSI-H). A similar pattern of gene transcription was seen for
MSH2. Although not significant, MSH2 transcription was again
marginally elevated in MSI-H compared to MSS or MSI-L cancers
(Figure 2). However, MSH2 transcription was elevated only in
MSI-H cancers (Po0.04; Figure 2) when compared to samples of
normal bowel, and not in MSS or MSI-L as seen with MLH1
transcription. There was a positive correlation between MLH1 and
MSH2 transcription (Po0.001, Pearson’s bivariate correlation).
Table 2 Demographics
Male Female Total
Site
Left colon 21 (54%) 18 (46%) 39 (58%)
Right colon 14 (50%) 14 (50%) 28 (42%)
Dukes’ stage
A 4 (67%) 2 (33%) 6 (9%)
B 17 (53%) 15 (47%) 32 (48%)
w
C 12 (50%) 12 (50%) 24 (36%)
w
D 2 (40%) 3 (60%) 5 (7%)
Micro-satellite status
MSS 21 (57%) 16 (43%) 37 (55%)
w
MSI-L 12 (67%)
z 6 (33%) 18 (27%)
MSI-H 2 (17%) 10 (83%)
z 12 (18%)
Demographic information, micro-satellite status, site of tumour and Dukes’ stage for
sporadic CRC analysed. Percentages in parentheses represent the percentage/gender
per MSI, site or Dukes’ stage group. Values of significance:
wPo0.001 and
zPo0.02,
both by w
2 test.
Table 3 Tumour site
Left colon Right colon Total
Micro-satellite status
MSS 24 (65%) 13 (35%) 37 (55%)
MSI-L 12 (67%) 6 (33%) 18 (27%)
MSI-H 3 (25%) 9 (75%)
w 12 (18%)
Dukes’ stage
A 6 (100%)
z 0(  ) 6 (9%)
B 17 (53%) 15 (47%) 32 (48%)
C 11 (46%) 13 (54%) 24 (36%)
D 5 (100%)
z 0(  ) 5 (7%)
Site of tumour with micro-satellite status and Dukes’ stage for CRC analysed.
Percentages in parentheses represent the percentage/site per MSI or Dukes’ stage
group. Values of significance:
wPo0.04 and
zPo0.03, both by w
2 test.
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Figure 1 Transcription of MLH1. Transcription of MLH1 in MSI cancers
and sections of normal bowel. Bars represent the mean valuesþs.e.m.
IOD, total integrated optical density of MLH1:GAP-3; each value
represents the overall mean value for all grouped samples, derived from
the mean of two separate PCR analyses per sample; see ‘Materials and
methods’. *Po0.01 vs MSS/MSI-L/MSI-H, one-way ANOVA with Bonfer-
roni’s correction.
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Figure 2 Transcription of MSH2. Transcription of MSH2 in MSI cancers
and sections of normal bowel. Bars represent mean valuesþs.e.m. IOD,
total integrated optical density of MSH2:GAP-3; each value represents the
overall mean value for all grouped samples, derived from the mean of two
separate PCR analyses per sample; see ‘Materials and methods’. *Po0.04 vs
MSI-H, one-way ANOVA with Bonferroni’s correction.
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in MSS and MSI-L cancers, p53 transcription was markedly
reduced in MSI-H cancers (Po0.003 vs MSS and MSI-L; Figure 3).
When compared to samples of normal bowel, p53 transcription
was elevated in MSS and MSI-L but reduced in MSI-H cancers, but
differences were not statistically significant (Figure 3). There was
an inverse correlation between MSI and p53 transcription
(Po0.002, Pearson’s bivariate correlation).
MLH1 and MSH2, and similarly p53 transcription, were not
related to Dukes’ stage, or site of tumour (results not shown).
MLH1 and MSH2 transcription was independent of mutations in
mono- or di-nucleotide markers (Figure 4). However, p53
transcription was markedly reduced when both mono- and di-
nucleotide makers mutated in comparison to the normal mono-
and di-nucleotides group (Po0.01; Figure 4C). Furthermore,
increasing ‘severity’ of mutation (in mono-, in di-, then in both
mono- and di-nucleotide markers) correlated with reduced
transcription of p53 (Po0.02, Pearson’s bivariate correlation; see
Figure 4C).
DISCUSSION
The discovery of MSI and the genes mediating MMR have
contributed greatly to our understanding of the process(es) of
tumorigenesis (Ionov et al, 1993; Peltomaki et al, 1993; Thibodeau
et al, 1993). Studies on tumours with MSI phenotype have until
recently remained restricted mainly to analyses of mutations in
DNA sequences or production of protein as measured by
immunohistochemistry. The importance of control of gene tran-
scription in tumorigenesis is particularly identifiable in MSI-H
cancers through silencing of gene transcription by hypermethylation
of sequences important in the control of the MMR genes
(Cunningham et al, 1998; Kuismanen et al, 1999). It was relevant,
therefore, to investigate the levels of transcription, that is, activity, of
the MMR genes MLH1 and MSH2, and the tumour-suppressor gene
p53 in sporadic CRC. This was achieved by utilising wax-embedded
specimens that allowed access to archival tissue for RT–PCR
analyses of the genes of interest on extracted total cellular RNA.
The study sample consisted of 55% of cancers of the MSS
phenotype, 27% MSI-L and 18% MSI-H, and, consistent with other
reports, the MSI-H cancers were predominant in females and in
the right colon (Boland et al, 1998; Thibodeau et al, 1998).
The prevalence of MSI-H in sporadic CRC has drawn attention
to methylation of MLH1 promoter regions as the potential
mechanism underlying MSI in these cancers (Cunningham et al,
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Figure 3 Transcription of p53. Transcription of p53 in MSI cancers and
sections of normal bowel. Bars represent mean valuesþs.e.m. IOD, total
integrated optical density of p53:GAP-3; each value represents the overall
mean value for all grouped samples, derived from the mean of two
separate PCR analyses per sample; see ‘Materials and methods’. *Po0.003
vs MSS and MSI-L, both one-way ANOVA with Bonferroni’s correction.
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Figure 4 Gene transcription with nucleotide markers. Transcription of
MLH1 (A), MSH2 (B) and p53 (C) in MSI cancers per nucleotide marker.
Bars represent the mean valuesþs.e.m. IOD, total integrated optical
density of Gene:GAP-3; each value represents the overall mean value for
all grouped samples, derived from the mean of two separate PCR analyses
per sample; see ‘Materials and methods’. Key to symbols: circles, mono-
nucleotide markers; squares, di-nucleotide markers; open symbols, normal
(non-mutated marker); closed symbols, mutated marker. *Po0.01 vs J&,
one-way ANOVA with Bonferroni’s correction. There was an inverse
correlation between mutated markers and p53 transcription, Po0.02,
Pearson’s bivariate correlation.
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s1998; Herman et al, 1998). Accordingly, in the specimens
examined, levels of MLH1 transcription were expected to be
reduced. However, MLH1 transcription was higher in all cancers
than in normal bowel, and, contrary to other studies (Kane et al,
1997; Cunningham et al, 1998; Herman et al, 1998; Kuismanen et al,
1999), was increased in MSI-H compared to MSS and MSI-L
cancers. Although contrary to current theories of gene expression
downregulation by methylation in MSI-H cancers (Cunningham
et al, 1998; Herman et al, 1998), a possible explanation for this
finding may be that the total cellular RNA extracted from the
paraffin-embedded samples might have included adjacent normal
tissue that expressed MLH1. Furthermore, should methylation
occur at only one allele (hemi-methylation), transcription could
still occur from the other nonmethylated allele (Cunningham et al,
1998; Kuismanen et al, 1999). However, as MLH1 mRNA was
amplified, it must have been available for translation to protein,
although on immunohistochemistry these cancers demonstrate
reduced MLH1 protein expression (Kane et al, 1997; Cunningham
et al, 1998; Herman et al, 1998; Kuismanen et al, 1999). Reduced
translation from mRNA to protein, or post-translational modifica-
tions of MLH1 rendering it less stable or with a reduced half-life
might explain these findings. Alternative mechanisms other than
DNA methylation might also be responsible, for example, the
mutation of genes such as MSH3 (Risinger et al, 1996), or
polymerase delta (da Costa et al, 1995). As 70–80% of MSI-H
cancers appear to be related to the epigenetic inactivation of MLH1
(Cunningham et al, 1998; Herman et al, 1998), in our samples, the
production of amplifiable mRNA for MLH1 suggests a post-
transcriptional mechanism as the basis for reduced MLH1 function
in these cancers. The pattern of MSH2 transcription was overall
similar to that of MLH1 and, accordingly, similar factors might be
involved. The direct association between increased transcription of
MLH1 and MSH2 with MSI might suggest that their activity is at
least in part co-ordinated, perhaps as an attempt to control the
higher mutation rate in MSI-H.
An intriguing finding was the reduction in p53 transcription in
MSI-H compared to normal bowel, and MSS or MSI-L cancers.
While studies on p53 mutation in MSI have shown conflicting
results, there is a consensus that p53 has an inverse relationship
with MSI (Cottu et al, 1996; Breivik et al, 1997; Olschwang et al,
1997; Forster et al, 1998; Iacopetta et al, 1998). The basis for the
apparent reduced rate of p53 mutations in the higher ‘mutator’
phenotype of MSI-H has remained unclear. Immunohistochem-
istry is widely used to identify p53 mutation, with overexpression
being regarded as a measure of mutation of the gene (Rodrigues
et al, 1990). However, the results from different studies should be
interpreted with caution, taking into consideration the processes of
tissue fixation and staining, the antibodies employed and the
scoring technique adopted. For example, differences in reported
rates of p53 mutation can be accounted for by the inconsistent
measurement of stained cells that varied from 5 to 30% in
determining if a cancer is mutated or not (Kim et al, 1994; Ilyas
et al, 1996; Iacopetta et al, 1998). Moreover, p53 overexpression
can occur in the absence of mutation due to the accumulation of
wild-type p53 in cancer cells (Cripps et al, 1994; Dix et al, 1994),
again highlighting the potential for mis-assigning p53 mutations in
MSI cancers if mutation is based on overexpression of p53 protein.
Alternatively, p53 may indeed be mutated, but remains largely
undetected as the resultant protein is truncated and so unligated
by the detecting antibody (Cripps et al, 1994; Dix et al, 1994).
Direct sequencing and SSCP also have their limitations in detecting
p53 mutations. With direct DNA sequencing, contamination from
normal DNA can mask the true result of tumour DNA analysis,
and although SSCP has been widely used for screening mutations
these have been mainly in exons 5–8 of p53 (Iacopetta, 2003), but
not other regions. In our samples, a reduced rate of p53
transcription to a level below that in normal bowel might explain
the reduced p53 function in these cancers. In addition and of equal
importance is that a reduced rate of p53 transcription would help
explain the apparent reduction of p53 mutations in MSI-H cancers
when this has been determined by the criteria of overexpression of
protein. Here, the reduced rate of transcription predisposes
reduced protein production, and, as fewer cells are detected
immunohistochemically as expressing p53, consequently the rate
of mutation judged by p53 overexpression is also reduced.
There is evidence that epigenetics plays an important role in
tumorigenesis. Toyota et al (1999) describe the CpG island
methylator phenotype (CIMP) to denote widespread methylation
of several genes implicated in the tumorigenic process(es).
Recently, methylation of p14 was observed in MSI-H cancers that
were CIMP positive and with fewer p53 mutations (Shen et al,
2003), although previously p14 promoter hypermethylation was
reported to be only marginally related to p53 mutation (Esteller
et al, 2000). p14 is a cell cycle regulatory protein known to interact
in vivo with MDM2, resulting in a decreased MDM2-mediated
degradation of p53 (Stott et al, 1998). Theoretically, as an upstream
regulator of p53 (via reducing degradation), when p14 is
inactivated via methylation, the resultant increase in MDM2 would
in turn reduce the availability of p53 and so potential tumour
suppression. Hence, methylation of p14 might obviate the need for
p53 mutation in tumorigenesis. The principle regulation of p53 is
by post-translational modification of the protein rather than at the
transcriptional level of the gene (Oren, 1999). However, the
difference in transcription of p53 between MSI-H and MSS/MSI-L
cancers in this study might suggest a role in MSI.
Cancer location has been associated with genetic differences
(Delattre et al, 1989; Gervaz et al, 2001). Infrequent loss of
heterozygosity (Delattre et al, 1989) and fewer p53 mutations
(Breivik et al, 1997) have been more commonly associated with
right-sided cancers. However, in this series, there was no
difference in the levels of gene transcription between cancers of
the left or right colon. Differences in the micro-environment of the
colon, or factors other than MLH1, MSH2 or p53 transcription, are
more likely to be involved. Transcription of MLH1 and MSH2 was
also independent of Dukes’ stage.
The NCI guidelines propose examination of two mono-
nucleotide and three di-nucleotide markers in order to classify
the MSI state (Boland et al, 1998). Mono-nucleotide markers are
relatively stable, nonpolymorphic, and are sensitive for the MSI-H
phenotype (Ionov et al, 1993; Dietmaier et al, 1997), while
instability in MSI-L is essentially restricted to di-nucleotide (or
longer) repeat markers (Dietmaier et al, 1997). A potential
problem arises, however, when there is a singular mutated
mono-nucleotide marker. In these cases, although such mutations
are sensitive for MSI-H (Ionov et al, 1993; Dietmaier et al, 1997;
and so may reflect an MSI-H-associated underlying mechanism),
the singular mutated marker would result in the MSI-L classifica-
tion. This was examined more closely by analysing the levels of
gene transcription in terms of MSI as well as mutations in mono-
or di-nucleotide markers.
Transcription of MLH1 and MSH2 was overall largely unaffected
by particular nucleotide mutations (see Figure 4), although there
was a slight, nonsignificant trend for the levels of transcription to
increase with increasing numbers of mutations. In contrast,
increasing ‘severity’ and number of mutations (in mono-, in di-,
then in both mono- and di-nucleotide markers) correlated overall
with reduced transcription of p53 (Po0.02; see Figure 4C).
However, it is important to note here that these tumours reflect
a large proportion of the MSI-H subgroup and therefore overall
with reduced p53 transcription (see Figure 3).
In conclusion, RT–PCR analysis of wax-embedded samples is
both feasible and of value. Of greater importance, however, is that
the reduced transcription of p53 in MSI-H emphasises a molecular
difference in this subgroup of cancers, in which the investigation
of molecules such as p14 and MDM2 in these cancers would help
clarify the role of p53 in MSI.
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